



Clinical Investigators' Day

October 6, 2017

Lecture Hall III



Cornell University College of Veterinary Medicine



Cornell University College of Veterinary Medicine

Welcome to the 2017 Clinical Investigators' Day, sponsored by the Cornell University College of Veterinary Medicine. The primary goal of this forum is to provide an opportunity for residents and interns to showcase ongoing investigations carried out at Cornell University College of Veterinary Medicine. It is our hope that greater insights will be gained in the breadth and depth of clinical investigations conducted at the College and will serve as a catalyst to promote greater interactions among colleagues with clinical and basic science research interests.

Organizing Committee

Ms. Gail Babcock
Dr. Elizabeth Buckles, Co-Chair
Dr. Jonathan Cheetham
Dr. Erin Daugherty, Co-Chair
Mr. Kim Eaton
Mr. Doug Fink
Ms. Kathleen Hall
Dr. Ursula Krotscheck
Dr. Mary Martin, Co-Chair
Ms. Suzette Moschetti
Dr. Santiago Peralta
Dr. Tracy Stokol, Co-Chair

The organizing committee thanks the following individuals who contributed to the success of the Day:

Mr. Andrew Amodeo
Mr. Dave Frank
Mr. Drew Kirby
Ms. Nancy Rice

Cover Photo Credit: Cornell University College of Veterinary Medicine - <https://www.instagram.com/p/BCLogsVITQs/?hl=en&taken-by=cornellvet>
© Cornell University College of Veterinary Medicine

Disclaimer: The information presented in this publication comes exclusively from the contributing authors and their mentors identified in each abstract. These abstracts are preliminary and should not be cited in bibliographies. Material contained herein may be treated as personal communication and should be cited as such only with the consent of the author.



Lauri-Jo Gamble, DVM, CCRP

lg497@cornell.edu

Institution and Location

Montreal University, St-Hyacinthe, Canada
Carolina Veterinary Specialists, Charlotte, North Carolina
VOSM, Annapolis Junction, Maryland
Cornell University, Ithaca, New York

Degree

DVM
Internship
Spec. Internship
Residency

Year

2014
2015
2016
2016-Present

Current Position

Resident, Sports Medicine and Rehabilitation, 2nd Year

Abstract Title:

Pilot Study on Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs

Authors Names:

Lauri-Jo Gamble¹, Christopher W. Frye¹, Erin S. Berthelsen¹, Sabine Mann¹, Jordyn M. Boesch¹, Joseph J. Wakshlag¹

¹Cornell University, College of Veterinary Medicine, Ithaca, New York

Project Mentor(s):

Joseph J. Wakshlag, DVM, PhD, ACVN, ACVSMR; Department of Clinical Sciences (Mentor)

Christopher W. Frye, DVM; Department of Clinical Sciences (Co-mentor)

Jordyn M. Boesch, DVM, DACVA; Department of Clinical Sciences (Co-mentor)

Abstract:

In the absence of an ideal treatment for chronic pain associated with osteoarthritis, there is an interest for cannabinoid derivatives, yet minimal scientific evidence regarding efficacy or safety in dogs. The objectives of this ongoing study were to determine the (1) basic oral pharmacokinetics, (2) general short term safety, and (3) efficacy of a novel cannabidiol extract (CBD) in dogs with multi-joint osteoarthritis.

A basic 24-hour oral pharmacokinetic study was performed at 2 different dosages (2mg/kg and 8mg/kg). Thereafter, sixteen client-owned dogs completed a placebo-controlled double-blind cross-over study. Dogs were randomly receiving CBD oil (2mg/kg ml/kg q12) or placebo oil for 4 weeks with 2 weeks washout period before cross-over. Veterinary assessments as well as owner questionnaires were completed at weeks 0, 2, and 4 for both oils.

Oral pharmacokinetics showed that half-life of elimination was 4.7 ± 1.2 hours with a 2 mg/kg dose. No obvious psychoactive properties were observed on neurological evaluation at any time point. On the clinical assessment, CBPI and Hudson scores showed a significant decrease in pain and increase in activity ($p \leq 0.01$) at week 2, while only Hudson activity indices were improved at week 4 for CBD oil ($p \leq 0.01$). ALP increased over time for 8 dogs while receiving CBD oil, reaching significance at week 4 ($p \leq 0.01$). We conclude that dogs with osteoarthritis receiving CBD oil are perceived to be more comfortable and active with very few undesirable side effects detected when compare to a placebo oil.